Work

Efficace trattamento con axicabtagene ciloleucel di una paziente con linfoma diffuso a grandi cellule B recidivato precocemente

Year: 2025

Type: article

Abstract: Refractoriness and early relapse after first-line therapy are two high-risk conditions for patients with diffuse large B-cell lymphoma (DLBCL). Nowadays, axicabtagene ciloleucel (axi-cel) is the therapeutic strategy to adopt in these clinical conditions, considering the results obtained in terms of overall survival and progression free survival in the ZUMA-7 trial. In the clinical case here reported, a female patient with an early relapsed triple expressor DLBCL was successfully treated with axi-cel, obtaining the complete remission at one month from therapy. Similarly, the adverse events onset after axi-cel were successfully and quickly treated.

Source: Recenti Progressi in Medicina

DOI: 10.1701/4450.44452

Author: Renato Scalone

Institution: La Maddalena

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: Gilead Sciences